MED12 and leiomyoma: MED12, implicated as an oncogene in about 70% of uterine leiomyoma [43,44], is a target of hsa-miR-10a-5p, whose expression is gradually reduced from AF-MSCS to L-MSCs, possibly explaining the upregulation of MED12 in leiomyoma.